Name
RETEPLASE
Mode of Action
RETEPLASE IS A THROMBOLYTIC DRUG. IT CONVERTS PLASMINOGEN TO PLASMIN, A PROTEOLYTIC ENZYME WHICH HAS FIBRINOLYTIC EFFECTS. THE MECHANISMS OF FIBRINOLYSIS ARE DISCUSSED FURTHER UNDER HAEMOSTASIS AND FIBRINOLYSIS ON. RETEPLASE HAS SOME FIBRIN SPECIFICITY (SEE THROMBOLYTICS. RETEPLASE IS USED SIMILARLY TO STREPTOKINASE IN ACUTE MYOCARDIAL INFARCTION
Dosage
BY INTRAVENOUS INJECTION (INITIATED WITHIN 12 HOURS), 10 UNITS OVER NOT MORE THAN 2 MINUTES, FOLLOWED AFTER 30 MINUTES BY A FURTHER 10 UNITS.
Drug Group
[THROMBOLYTIC] , [TISSUE PLASMINOGEN ACTIVATOR] , [FIBRINOLYTIC]
Cross Reaction
HEPARIN AND VITAMIN K ANTAGONISTS & DRUGS THAT ALTER PLATELET FUNCTION (SUCH AS ASPIRIN, DIPYRIDAMOLE, AND ABCIXIMAB) MAY INCREASE THE RISK OF BLEEDING IF ADMINISTERED PRIOR TO OR AFTER RETEPLASE THERAPY.
Drug Interaction
Drugs Side Effect
Drug Categories
Special Precaution
Drug Safety
Monograph